{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","spread":"3.342","upperLimit":"1.00","value":"5.62"},{"groupId":"OG001","lowerLimit":"NA","spread":"1.792","upperLimit":"NA","value":"4.09"}]}],"title":"Baseline (n: = 41, 14)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.68","spread":"2.551","upperLimit":"0.94","value":"3.50"},{"groupId":"OG001","lowerLimit":"NA","spread":"6.919","upperLimit":"NA","value":"5.17"}]}],"title":"Week 4 (n: 38, 15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Compare estradiol concentrations from baseline to week 4 in both treatment arms.","dispersionType":"Standard Deviation","groups":[{"description":"Everolimus 10 mg daily in combination with exemestane 25 mg daily","id":"OG000","title":"Everolimus + Exemestane"},{"description":"Placebo of everolimus in combination with exemestane 25 mg daily","id":"OG001","title":"Placebo + Exemestane"}],"paramType":"MEAN","populationDescription":"Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose \\& 2 hours post-dose values for the given time points were analyzed for that time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 4","title":"Estradiol Plasma Concentrations","type":"SECONDARY","unitOfMeasure":"pg/mL"}